Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Nihon Medi-Physics Expands Consultation Services Regarding PET-CT
April 17, 2006
- Kissei Licenses Novel Diabetes Treatment to GSK
April 17, 2006
- Daiichi to Market Intrathecal Gagalon with Synchromed Infusion System
April 17, 2006
- Astellas Acquires Worldwide Rights to Amevive
April 17, 2006
- MEDICAL DEVICE NEWS IN BRIEF
April 17, 2006
- Kirin, Intercell to Develop Antibodies to Treat Pneumonia
April 17, 2006
- JMA's Relationship with LDP Needs Mending: Dr Karasawa
April 17, 2006
- NEW BOOK
April 10, 2006
- SEMINAR
April 10, 2006
- Growing Need for Generics with High Added Value: Prof. Ueno
April 10, 2006
- Daiichi Sankyo Acquires Zepharma
April 10, 2006
- Astellas, Toyama Ink Licensing Agreement on New Quinolone T-3811
April 10, 2006
- Market for Bio-derived Materials to Grow 54% by 2010: Fuji-Keizai
April 10, 2006
- Astellas Switches to Disease-Based 2-Line Marketing System
April 10, 2006
- SELF-MEDICATION NEWS IN BRIEF
April 10, 2006
- Deloitte Touche Tohmatsu Forms "Pharma Team" to Support Life Science Industry
April 10, 2006
- OPINION
April 10, 2006
- Janssen Pharm. Reports 7th Year of Double-Digit Growth
April 10, 2006
- HUMAN RESOURCES NEWS IN BRIEF
April 10, 2006
- Yoh Narimatsu Appointed President and CEO of Quintiles Japan
April 10, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…